Treatment with oral ubrogepant (Ubrelvy) during the migraine prodrome led to more patients being able to function normally, a prespecified secondary endpoint analysis of the phase III PRODROME trial ...

Absence of photophobia at 2 hours postdose occurred in 19.5 and 12.5% of ubrogepant- and placebo-treated events, respectively. HealthDay News — Ubrogepant during the prodromal phase of migraine may ...

The researchers found that after treatment of qualifying prodrome events, participants after ubrogepant treatment had a significantly greater ability to function normally over 24 hours than those ...

Treating migraine before the pain starts: New research shows ubrogepant eases premonitory symptoms, offering hope for millions seeking earlier and more effective relief. Study: Ubrogepant for the ...

Please provide your email address to receive an email when new articles are posted on . Treatment with 100 mg of ubrogepant in the prodromal phase prevented development of headaches as soon as 24 ...

On the heels of favorable results from the phase 3 ACHIEVE-I trial, which were presented last week at the American Academy of Neurology (AAN) 2018 Annual Meeting, topline results from the phase 3 ...

Please provide your email address to receive an email when new articles are posted on . A higher percentage of patients with migraine who received ubrogepant — an experimental treatment — experienced ...

Ubrogepant, the newly approved calcitonin gene-related peptide antagonist, can relieve migraine symptoms within 2 hours after initial dose. Ubrogepant has been shown to relieve migraine pain and ...

Allergan's ubrogepant is on a roll—the oral CGRP drug has hit the mark in a second phase 3 migraine trial, cementing the company's plans to file for approval in 2019. The 1,686-patient study tested a ...

(CNN) -- A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options. The drug, ubrogepant, showed greater rates of ...

The drug, ubrogepant, showed greater rates of pain and symptom relief from migraine compared to a placebo, with more than 20% of participants given the drug reporting to be pain-free within two hours ...

The clinical utility of the calcitonin gene–related peptide (CGRP) receptor antagonist ubrogepant may extend beyond the treatment of acute migraine to alleviating common prodromal symptoms of migraine ...